Related Experiment Video
Updated: May 28, 2026
Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate
Zhaoxu Li1, Huiqin Peng, Qiang Xu
1Department of Orthopaedics, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China.
Abstract:
Despite improvements in the treatment of osteosarcoma, there is a need for new therapeutic strategies, in particular for the treatment of recurrent tumors and metastases. Adoptive immunotherapy with Vγ9Vδ2 T lymphocytes represents an attractive strategy. We have investigated combining adoptive immunotherapy with Vγ9Vδ2 T cells and zoledronate to optimize osteosarcoma therapy. Vγ9Vδ2 T cells, from healthy volunteers and patients with osteosarcoma, cultures alone demonstrated moderate or poor cytotoxic activity against osteosarcoma cell lines, respectively. The addition of zoledronate further increased cytotoxicity in vitro. This enhancement was largely dependent on the granule exocytose and partly on TRAIL pathways, was TCR-mediated and partly NKG2D-mediated. These data suggest that combined treatment of human osteosarcoma with zoledronate and Vγ9Vδ2 T cells may be an effective complement to current chemotherapies.
Insights
Combining zoledronate with V gamma 9 V delta 2 T cell immunotherapy enhances the treatment of osteosarcoma, particularly for recurrent tumors and metastases. This novel approach shows promising cytotoxic activity against osteosarcoma cells in vitro.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Biology
Background:
- Osteosarcoma treatment requires novel strategies, especially for recurrent disease and metastasis.
- Adoptive immunotherapy using V gamma 9 V delta 2 T lymphocytes is a promising therapeutic avenue.
Purpose of the Study:
- To investigate the combination of adoptive immunotherapy with V gamma 9 V delta 2 T cells and zoledronate for osteosarcoma treatment.
- To evaluate the efficacy and mechanisms of this combined therapy in vitro.
Main Methods:
- Culturing V gamma 9 V delta 2 T cells from healthy volunteers and osteosarcoma patients.
- Assessing cytotoxic activity against osteosarcoma cell lines with and without zoledronate.
- Investigating the involvement of granule exocytosis, TRAIL, TCR, and NKG2D pathways.
Main Results:
- V gamma 9 V delta 2 T cells alone showed moderate to poor cytotoxic activity against osteosarcoma cells.
- Zoledronate significantly enhanced T cell-mediated cytotoxicity in vitro.
- The enhancement was dependent on granule exocytosis and TRAIL pathways, and mediated by TCR and NKG2D.
Conclusions:
- Combined zoledronate and V gamma 9 V delta 2 T cell therapy demonstrates potential as an effective addition to current osteosarcoma chemotherapies.
- This strategy may offer improved treatment options for recurrent osteosarcoma and metastases.
